sorafenib has been researched along with Hemolysis in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, HK; Kim, HY; Ko, HW; Lee, H; Lee, YJ; Mo, L; Song, JG; Zhao, M | 1 |
| Ali, S; Khan, MA; Ovais, M; Raza, A; Sohail, MF; Venkatraman, SS | 1 |
| Amore, E; Augello, G; Bondì, ML; Botto, C; Cervello, M; Craparo, EF; Emma, MR | 1 |
| Choi, HG; Choi, JY; Gupta, B; Hiep, TT; Kim, JO; Pathak, S; Poudel, BK; Thapa, RK; Yong, CS | 1 |
| Amore, E; Azzolina, A; Balasus, D; Bondì, ML; Botto, C; Cervello, M; Mazzaglia, A; Scala, A; Sortino, G | 1 |
| Correia, A; De Stefano, L; Lamberti, A; Rea, I; Santos, HA; Shahbazi, MA; Terracciano, M | 1 |
| Gong, X; Liu, Y; Wang, T; Yang, S; Zhang, B; Zhang, N | 1 |
| Choi, HG; Choi, JY; Kim, JO; Poudel, BK; Thapa, RK; Yong, CS | 1 |
| Chen, L; Liu, H; Liu, J; Liu, Y; Wang, X; Wang, Z; Yang, J | 1 |
| Berchem, G; Dewilde, S; Mahassen, P | 1 |
| Cui, Z; He, B; Qu, W; Wang, JC; Wang, YB; Zhang, H; Zhang, JY; Zhang, Q | 1 |
| Bitzer, M; Föller, M; Jilani, K; Lang, E; Lang, F; Lupescu, A; Pasham, V; Plate, A; Qadri, SM; Shaik, N; Zbidah, M; Zelenak, C | 1 |
| Chow, S; Hedley, D; Tong, FK | 1 |
1 trial(s) available for sorafenib and Hemolysis
| Article | Year |
|---|---|
Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antigens, CD34; Antigens, Differentiation, Myelomonocytic; Benzenesulfonates; CD13 Antigens; CD3 Complex; Drug Monitoring; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Hemolysis; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; MAP Kinase Signaling System; Middle Aged; Models, Biological; Myelodysplastic Syndromes; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Sorafenib; Stem Cell Factor; Stem Cells; Tetradecanoylphorbol Acetate | 2006 |
12 other study(ies) available for sorafenib and Hemolysis
| Article | Year |
|---|---|
PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Drug Carriers; Drug Delivery Systems; Female; Hemolysis; Humans; Hyaluronic Acid; Liposomes; Mice; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: An approach for improved oral pharmacokinetics of Sorafenib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Butadienes; Cell Survival; Drug Carriers; Drug Liberation; Erythrocytes; Hemolysis; Hep G2 Cells; Humans; Inhibitory Concentration 50; Male; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Polyethylene; Protein Kinase Inhibitors; Sorafenib | 2018 |
Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells.
Topics: Antineoplastic Agents; Caprylates; Cell Survival; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Hemolysis; Hep G2 Cells; Humans; Lipids; Microscopy, Electron, Scanning; Nanoparticles; Niacinamide; Particle Size; Phenylurea Compounds; Sorafenib; Triglycerides | 2015 |
Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma.
Topics: Animals; Apoptosis; Calorimetry, Differential Scanning; Carcinoma, Hepatocellular; Cell Survival; Drug Carriers; Drug Liberation; Erythrocytes; Hemolysis; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liquid Crystals; Liver Neoplasms; Male; Microscopy, Atomic Force; Microscopy, Electron, Transmission; Nanoparticles; Niacinamide; Phenylurea Compounds; Polymers; Rats; Rats, Sprague-Dawley; Sorafenib; Spectroscopy, Fourier Transform Infrared | 2015 |
Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells.
Topics: Adamantane; Antineoplastic Agents; Binding, Competitive; Cell Line, Tumor; Cell Survival; Cyclodextrins; Delayed-Action Preparations; Drug Compounding; Drug Liberation; Erythrocytes; Hemolysis; Hepatocytes; Humans; Kinetics; Nanostructures; Niacinamide; Phenylurea Compounds; Sorafenib; Surface-Active Agents | 2015 |
Surface bioengineering of diatomite based nanovectors for efficient intracellular uptake and drug delivery.
Topics: Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Cell-Penetrating Peptides; Diatomaceous Earth; Drug Carriers; Drug Delivery Systems; Erythrocytes; Hemolysis; Humans; Hydrogen-Ion Concentration; MCF-7 Cells; Microscopy, Confocal; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanoparticles; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Propylamines; Silanes; Solubility; Sorafenib; Spectroscopy, Fourier Transform Infrared; Water | 2015 |
In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Biocompatible Materials; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Drug Liberation; Female; Hemolysis; Humans; Inhibitory Concentration 50; Lipids; Liver Neoplasms; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Suspensions; Tissue Distribution; Treatment Outcome; Veins | 2016 |
Receptor-targeted, drug-loaded, functionalized graphene oxides for chemotherapy and photothermal therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Death; Drug Carriers; Endocytosis; Folate Receptors, GPI-Anchored; Folic Acid; Graphite; Hemolysis; Humans; Hyperthermia, Induced; KB Cells; Male; Nanomedicine; Niacinamide; Phenylurea Compounds; Phototherapy; Rats; Sorafenib; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2016 |
In vitro and in vivo evaluation of redox-responsive sorafenib carrier nanomicelles synthesized from poly (acryic acid) -cystamine hydrochloride-D-α-tocopherol succinate.
Topics: Acrylic Resins; alpha-Tocopherol; Animals; Cell Line, Tumor; Chemistry Techniques, Synthetic; Cystamine; Drug Carriers; Drug Liberation; Hemolysis; Humans; Hydrophobic and Hydrophilic Interactions; Male; Micelles; Nanostructures; Niacinamide; Oxidation-Reduction; Particle Size; Phenylurea Compounds; Rabbits; Rats; Sorafenib; Stereoisomerism | 2016 |
A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hemoglobins; Hemolysis; Humans; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cattle; Cell Line, Tumor; Drug Carriers; Female; Hemolysis; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Nanoparticles; Neoplasms; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Serum Albumin, Bovine; Sorafenib | 2011 |
Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: an in vivo and in vitro study.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Size; Ceramides; Erythrocytes; Hemolysis; Humans; Liver Neoplasms; Niacinamide; Oxidative Stress; Phenylurea Compounds; Phosphatidylserines; Protein Kinase Inhibitors; Sorafenib | 2012 |